SCHEMBL24124207

SCHEMBL24124207

CN1C(=O)CSc2ccc(C(=O)Cl)cc21

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.76
SMN1; SMN2 Q16637 3/20 0.71
POLB P06746 2/20 0.71
MAPT P10636 11/20 0.58
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
ALDH1A1 P00352 3/20 0.54
HTT P42858 4/20 0.53
MAPK1 P28482 7/20 0.53
ALOX15 P16050 2/20 0.53
USP2 O75604 2/20 0.53
TP53 P04637 2/20 0.53
OPRM1 P35372 1/20 0.51
OPRD1 P41143 1/20 0.51
HSD17B10 Q99714 1/20 0.50
CLK1 P49759 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPC1 O15118 1/20 0.47
TSHR P16473 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30270575 1.00 LMNA (0.76) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL5912909 0.87 LMNA (0.78) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL30270516 0.87 LMNA (1.00) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL18618415 0.83 LMNA (0.72) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL25920690 0.83 LMNA (0.53) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL5422370 0.83 POLB (1.00) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL25920688 0.82 ALDH1A1 (0.65) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL10651410 0.82 LMNA (0.71) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL24125232 0.81 LMNA (0.51) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL10808494 0.78 LMNA (0.61) LMNASMN1; SMN2POLBMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 LMNA 4265/4885SMN1; SMN2 4270/4885POLB 2630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.